1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

Awaiting development [GID-TA11494] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN - 25409-Ruxolitinib-for-Graft-Versus-Host-Disease-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)